TPD & Induced Proximity Summit Leaderboard

Thursday, July 2, 2026
About
Advertise
Subscribe
Contact

Pharma Journalist -

Home
News
Drug Research
Clinical Trials
Manufacturing
Information Technology
Packaging & Labeling
Diseases
Resources
Events
Press Releases

Home
Events

Browsing

e

Jul 2, 2026

Read More...

About Us

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts

Zymeworks to Acquire Theravance Biopharma in $929 Million Deal
EMA Panel Backs Lilly’s Jaypirca for Chronic Lymphocytic Leukemia
Talawar Therapeutics Announces $285 Million Nasdaq Merger Deal
AstraZeneca, YMCA Launch National Cancer Education Partnership
Antares, Novartis Partner on Cancer Drug Discovery

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

About
Advertise
Subscribe
Contact

© 2026 - Pharma Journalist. All Rights Reserved.

Pharma Journalist is a product of

Sign in

Welcome, Login to your account.

Forget password? Remember me

Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.